Accolades: Awards, honors and appointments September
Expertos de OHSU ofrecen consejos sobre cómo navegar la era de la "posverdad"
OHSU experts give advice on navigating a ‘post-truth’ era
A promising new target for cancer immunotherapy
Robert L. Eil, M.D., is co-senior author of a new study in Science that identifies a previously unknown way tumors escape immune attack and points to a promising new target for cancer immunotherapy. (OHSU/Christine Torres Hicks)
Las células cancerosas utilizan una proteína antioxidante para suprimir las células T y resistir la inmunoterapia, según un estudio.
Robert L. Eil, M.D., es coautor principal de un nuevo estudio publicado en Science que identifica una vía, hasta ahora desconocida, mediante la cual los tumores eluden el ataque del sistema inmunitario y señala una nueva y prometedora diana para la inmunoterapia contra el cáncer. (OHSU/Christine Torres Hicks)
Cancer cells use antioxidant protein to suppress T cells, resist immunotherapy, study finds
Las células cancerosas utilizan una proteína antioxidante para suprimir las células T y resistir la inmunoterapia, según un estudio
Oregon releases plan to reduce the burden of cancer statewide
Brian Druker, M.D., CEO, OHSU Knight Cancer Institute, is pictured upper left, and Jackie Shannon, Ph.D., associate director of community outreach and engagement at the OHSU Knight Cancer Institute and professor in the Division of Oncological Sciences (population science) in the OHSU School of Medicine, is pictured lower right. OHSU’s Knight Cancer Institute and the Oregon Health Authority, or OHA, led the creation of the 2025 Comprehensive Cancer Control Plan, meant to reduce the burden of cancer in the state of Oregon. (OHSU/Christine Torres Hicks)
Accolades: Awards, honors and appointments August
